Dr. David Kessler, Chief Scientist for Biden Administration, Calls for Proactive Use of Monoclonal Antibodies to Treat COVID-19

All we can say is: finally! While it is long overdue, we were delighted to see Dr. David Kessler, the Chief Scientist for the Biden Administration’s COVID-19 Task Force, in an interview with Rachel Madow of MSNBC, give a full throated endorsement and call for both the public and medical community to embrace and use […]

WSJ: Regeneron Antibody Drug Temporarily Protects Against Covid-19, Preliminary Data Show

Regeneron Pharmaceuticals Inc. REGN -4.07% said its antibody drug reduced coronavirus infections by half in people at high risk, a preliminary sign the therapy could be given to temporarily prevent Covid-19. None of the patients receiving the drug developed symptoms from the virus, Regeneron said Tuesday, providing an interim analysis of a continuing study. Given […]

IDSA Podcast: COVID-19: The Latest on Monoclonal Antibodies

This week’s COVID-19 podcast by the Infectious Disease Society of America focused on the critical information that physicians – and the public – need to understand about Monoclonal Antibody therapeutics now available from Pfizer and Regeneron. How do monoclonal antibody treatments help combat COVID-19? In this episode, we discuss the latest information on monoclonal antibodies […]

NIH Panel Highlights Early Use of Antibody Therapies for Outpatients at High Risk of Disease Progression

In a little noticed update on December 3rd, the NIH COVID-19 Treatment Guidelines for Therapeutic Management of Patients with COVID-19 now clearly highlights – with appropriate caveats – that physicians consider the early use of antibody therapies for outpatients who are at high risk for disease progression. In the earliest stages of infection, before the […]

Scroll to top